DHEA Replacement vs. No DHEA in Addison's Disease: What the Evidence Shows

Why DHEA Deficiency Is a Separate Problem in Addison's Disease

Addison's disease destroys the adrenal cortex across all three zones. The zona glomerulosa stops making aldosterone, the zona fasciculata stops making cortisol, and the zona reticularis stops making dehydroepiandrosterone (DHEA) and its sulfated form DHEAS. Standard replacement therapy addresses the first two deficiencies with hydrocortisone and fludrocortisone. DHEA is left out entirely.

DHEAS is the most abundant circulating steroid in healthy adults. Women aged 20, 30 carry serum DHEAS concentrations of roughly 150 to 300 mcg/dL; men carry 200 to 400 mcg/dL. In autoimmune Addison's disease, DHEAS drops to levels often below 15 mcg/dL, which represents a near-total absence of adrenal androgen output [1]. The ovaries and testes contribute some DHEA but cannot compensate for the loss of adrenal production.

DHEA is a precursor to both testosterone and estradiol in peripheral tissues. Adipose, skin, bone, and brain all carry the enzymes to convert circulating DHEA locally. This intracrine conversion means DHEA delivers androgenic and estrogenic signals without raising serum sex-steroid levels proportionally. That local conversion is why oral DHEA replacement at 25 to 50 mg/day can restore serum DHEAS to the mid-normal range for age without causing supraphysiologic testosterone or estradiol concentrations in most patients [2].

Patients with Addison's disease who are fully replaced on hydrocortisone and fludrocortisone frequently report persistent fatigue, low mood, reduced libido, and diminished general well-being. These symptoms overlap substantially with known consequences of DHEA deficiency in other clinical settings, which is what generated interest in adding DHEA to the standard regimen.

What Controlled Trials Show About DHEA vs. Placebo

The 1999 trial by Arlt and colleagues, published in the New England Journal of Medicine, was the first high-quality crossover RCT to test DHEA 50 mg/day versus placebo in 24 patients with adrenal insufficiency (both primary and secondary) [3]. After four months of DHEA, women showed significant improvements in overall well-being, mood, fatigue, and sexual interest. Men showed smaller and less consistent benefits. Serum DHEAS normalized into the age-appropriate reference range in both sexes.

A larger crossover RCT by Hunt et al. (2000), published in the Journal of Clinical Endocrinology and Metabolism, enrolled 39 women with primary adrenal insufficiency and tested DHEA 50 mg/day for three months versus placebo [4]. The trial confirmed improved psychological well-being (measured by the GHQ-28 and CES-D) and reported significant increases in sexual interest and sexual enjoyment.

The DHEA replacement trial by Gurnell et al. (2008) ran for two years in 101 patients with hypopituitarism, making it among the longest placebo-controlled evaluations of DHEA in adrenal insufficiency populations [5]. Lumbar spine bone mineral density improved by a mean of 1.7% in the DHEA arm versus no change in placebo (P<0.05). Fatigue and well-being scores improved modestly but did not reach significance on all scales. The longer duration suggested that some benefits accumulate over time.

A meta-analysis by Gan et al. (2015), covering 10 RCTs and 967 participants with adrenal insufficiency, found that DHEA significantly improved health-related quality of life (standardized mean difference 0.22 to 95% CI 0.03, 0.41) and reduced depressive symptoms [6]. Anxiety scores and sexual function also improved significantly. Bone mineral density effects were heterogeneous across studies. The authors concluded that the benefit is real but modest in magnitude, and that women derive more consistent benefit than men.

These findings collectively suggest that the question is not "does DHEA work" but rather "for which patients does the benefit justify the monitoring burden."

Who Benefits Most from DHEA Replacement

Women with Addison's disease show the most consistent quality-of-life response to DHEA. The reason is straightforward: in women, adrenal androgens account for roughly 50% of total androgen production, so adrenal destruction causes a proportionally larger androgenic deficit than it does in men, whose testes continue producing testosterone [7].

Premenopausal women with Addison's disease who report low libido, persistent fatigue, or low mood despite adequate hydrocortisone and fludrocortisone dosing are the group most likely to respond. Postmenopausal women may also benefit, particularly those not using systemic estrogen or testosterone therapy, because their residual sex-steroid production depends heavily on peripheral DHEA conversion.

Men with Addison's disease have less compelling trial data supporting DHEA replacement. Testicular testosterone output partially compensates for lost adrenal DHEA. Men who are hypogonadal in addition to having Addison's may benefit, but in that case direct testosterone replacement is usually more appropriate than DHEA supplementation alone.

Children and adolescents with Addison's disease should not receive DHEA replacement routinely. The adrenal zona reticularis does not mature until adrenarche, and exogenous DHEA before puberty is complete could advance bone age or cause virilization.

The Standard Hydrocortisone Regimen: Conventional vs. Modified Release

Any discussion of DHEA replacement must sit within the broader context of glucocorticoid replacement, because suboptimal cortisol dosing mimics symptoms of DHEA deficiency and confounds treatment response.

Conventional Hydrocortisone

The current Endocrine Society guideline (2016) recommends hydrocortisone 15 to 25 mg/day in two or three divided doses as first-line glucocorticoid replacement in Addison's disease [8]. The typical split is 10 mg on waking, 5 mg at noon, and 5 mg in the early afternoon (or 10 mg plus 5 mg in a two-dose regimen). Conventional immediate-release hydrocortisone produces sharp cortisol peaks followed by troughs, which does not replicate the normal circadian cortisol profile.

Peak-and-trough pharmacokinetics matter. The normal cortisol awakening response generates a sharp morning peak within 30 to 45 minutes of waking and a gradual afternoon decline reaching near-zero by midnight. Conventional hydrocortisone roughly mimics this, but patients who take their first dose late, skip a midday dose, or absorb tablets variably can spend hours in cortisol troughs that produce fatigue and malaise indistinguishable from DHEA deficiency symptoms.

Modified-Release Hydrocortisone (Plenadren)

Once-daily modified-release hydrocortisone (Plenadren, approved in Europe; investigational use in the United States) releases hydrocortisone over several hours, producing a cortisol profile closer to physiologic. The DREAM trial (N=64), a randomized crossover study published in the Journal of Clinical Endocrinology and Metabolism (2017), showed that Plenadren at equivalent doses produced significantly lower 24-hour cortisol exposure and better quality-of-life scores than conventional thrice-daily hydrocortisone [9]. Patients on Plenadren also showed improvements in metabolic markers including insulin sensitivity, suggesting that supraphysiologic morning cortisol peaks from conventional dosing cause metabolic harm over time.

From a practical standpoint, modified-release hydrocortisone is worth considering before attributing residual symptoms to DHEA deficiency. A patient whose persistent fatigue resolves after switching from conventional to modified-release hydrocortisone may not need DHEA at all.

Hydrocortisone vs. Prednisone

Prednisone 3 to 5 mg once daily (or prednisolone 3 to 4 mg/day) is sometimes used as a simpler once-daily alternative to hydrocortisone. The longer half-life of prednisone allows once-daily dosing, which improves adherence. The trade-off is that prednisone is more potent per milligram, has a less flexible dose-adjustment range, and lacks the well-established pharmacokinetic database that exists for hydrocortisone in Addison's disease.

No large head-to-head trial has compared prednisone and hydrocortisone specifically for quality-of-life outcomes in Addison's disease. Observational data suggest that patients on prednisone may have higher rates of metabolic side effects (weight gain, glucose intolerance) given the less granular dosing and the more pronounced mineralocorticoid overlap at higher doses. The Endocrine Society guideline favors hydrocortisone over prednisone as the preferred agent because its shorter half-life allows more physiologic dosing flexibility.

How to Add DHEA to an Existing Regimen

If the treating clinician decides to trial DHEA in a woman with Addison's disease and persistent quality-of-life impairment, the protocol used in most trials is straightforward.

Start at 25 mg once daily in the morning. Taking DHEA in the morning matches the normal adrenal secretion pattern and avoids the theoretical issue of elevated DHEA metabolites during sleep. After 6 to 12 weeks, check serum DHEAS. The target is the mid-to-upper end of the age-adjusted female reference range, approximately 100 to 250 mcg/dL for women aged 20, 50.

If DHEAS remains below target and the patient tolerates the initial dose without androgenic side effects, increase to 50 mg/day. Most trials used 50 mg as the ceiling dose for women. Going higher risks acne, oily skin, hirsutism, and occasionally clitoral sensitivity changes. Check DHEAS, total testosterone, and sex-hormone-binding globulin (SHBG) at each dose adjustment.

A formal 3 to 6 month trial is appropriate before declaring DHEA effective or ineffective for a given patient. Quality-of-life tools like the AddiQoL (Addison's disease quality-of-life questionnaire) or the SF-36 provide structured ways to document change.

If the patient shows no meaningful improvement in well-being, libido, or mood after 6 months at 50 mg/day with confirmed DHEAS normalization, discontinue DHEA. There is no benefit to continuing a treatment that is not producing an effect the patient notices.

HealthRX Clinical Decision Framework: DHEA Replacement in Addison's Disease

Use this stepwise framework before initiating DHEA:

1. Confirm glucocorticoid optimization. Is the patient on hydrocortisone 15 to 25 mg/day in 2, 3 doses (or equivalent)? Is the dose split appropriate for their daily schedule? Have they tried modified-release hydrocortisone if symptoms persist on conventional dosing?
2. Confirm mineralocorticoid adequacy. Fludrocortisone 0.05 to 0.2 mg/day with appropriate sodium intake. Standing blood pressure drop of more than 20 mmHg systolic suggests under-replacement.
3. Measure baseline DHEAS. If DHEAS is already above 100 mcg/dL (unusual but possible in mild or partial adrenal insufficiency), the rationale for DHEA supplementation weakens considerably.
4. Identify the symptom target. Is it mood, libido, energy, or general well-being? Score it with AddiQoL or SF-36 at baseline.
5. Start DHEA 25 mg/day in the morning in women with clear deficiency (DHEAS <50 mcg/dL) and at least one of the above symptoms unresponsive to optimized conventional therapy.
6. Check DHEAS, total testosterone, and SHBG at 6 to 12 weeks. Titrate to 50 mg/day if needed.
7. Re-score quality of life at 3 and 6 months. Continue if measurable benefit. Stop if no benefit after 6 months.

Monitoring Parameters and Safety

DHEA is generally well-tolerated at 25 to 50 mg/day in women with Addison's disease. The most common side effects are androgenic: acne, oily skin, and mild hirsutism. In the Hunt 2000 trial (N=39), 23% of women on DHEA 50 mg reported acne versus 5% on placebo, and 18% reported increased facial hair versus 3% on placebo [4]. These effects were rated mild by most participants and did not lead to discontinuation.

Rare but documented concerns include:

• Polycythemia in men if DHEA is converted peripherally to testosterone
• Worsening of hormone-sensitive conditions (e.g., history of hormone receptor-positive breast cancer; DHEA is relatively contraindicated in this group)
• Interactions with aromatase activity in women who are also using estrogen replacement (DHEA conversion to estradiol could theoretically add to exogenous estrogen exposure)

Annual monitoring of DHEAS, total testosterone, and a lipid panel is reasonable. DHEAS above the upper limit of the reference range (above approximately 380 mcg/dL in premenopausal women) should prompt dose reduction.

Adrenal Crisis Prevention: Not DHEA's Role

One common misconception deserves direct correction. DHEA replacement does not prevent adrenal crisis. Adrenal crisis is a glucocorticoid and mineralocorticoid emergency, not a DHEA emergency.

The Addison's patient must carry an emergency hydrocortisone injection kit (typically hydrocortisone sodium succinate 100 mg IM/IV) and wear medical alert identification. Sick-day rules require doubling or tripling oral hydrocortisone during febrile illness or physiologic stress. DHEA does not replace the need for this stress-dosing protocol.

The Endocrine Society guideline states: "We recommend that all patients with AI [adrenal insufficiency] receive education about stress dosing of glucocorticoids and parenteral glucocorticoid self-administration or administration by a caregiver" [8]. DHEA has no role in that emergency protocol.

What the Endocrine Society and European Guidelines Say

The 2016 Endocrine Society Clinical Practice Guideline on Diagnosis and Treatment of Primary Adrenal Insufficiency conditionally recommends a trial of DHEA 25 to 50 mg/day in women with Addison's disease who have reduced quality of life or persistent depression despite optimized conventional replacement [8]. The recommendation is graded 2|OOO (very low-quality evidence, conditional recommendation), meaning the guideline committee judged potential benefit to outweigh potential harm for appropriately selected patients, but the evidence base is not strong enough for a blanket recommendation.

The European Reference Network on Rare Endocrine Conditions (Endo-ERN) consensus statement on adrenal insufficiency similarly endorses considering DHEA for women with reduced quality of life, and specifies checking DHEAS before starting to confirm deficiency, rather than treating empirically [10].

Neither guideline recommends routine DHEA replacement for all Addison's patients, and neither recommends it for men unless there is a specific clinical rationale.

Practical Sourcing and Formulation Considerations

In the United States, pharmaceutical-grade DHEA is not an FDA-approved prescription drug in the traditional sense, but it is legally available as an over-the-counter dietary supplement. The FDA has not approved any DHEA product for adrenal insufficiency. This creates a quality-control issue: studies of DHEA supplements sold without prescription have found significant variation in actual DHEA content versus label claims.

For patients with Addison's disease, compounded pharmaceutical-grade DHEA from a licensed compounding pharmacy, obtained through a prescription, is the more reliable option because it is subject to at least some quality oversight. The prescribing clinician should specify the dose (25 or 50 mg), the form (typically immediate-release oral capsule), and the morning administration schedule.

Serum DHEAS measured 4 to 6 hours after the morning dose provides a useful peak-level check. Trough DHEAS (measured 20 to 24 hours after the previous dose) gives insight into whether adequate levels are maintained through the day.

Comparing Outcomes: DHEA vs. No DHEA at a Glance

To summarize the trial evidence quantitatively: the Gan 2015 meta-analysis of 10 RCTs (N=967) found that DHEA produced a standardized mean difference of 0.22 (95% CI 0.03, 0.41) in health-related quality of life scores compared to placebo [6]. That translates to a small but statistically significant effect. In practical terms, roughly 1 in 5 women with Addison's disease on optimized hydrocortisone and fludrocortisone may notice a clinically meaningful improvement in mood or libido from adding DHEA 25 to 50 mg/day.

That number is not large. It means most patients will not perceive a striking difference. The appropriate response to this is not to dismiss DHEA universally, but to trial it in symptomatic patients, measure the response objectively, and discontinue it if no benefit is apparent after 6 months.

The absence of serious safety signals in published trials, combined with the near-certain DHEA deficiency in every patient with Addison's disease, supports offering a structured trial to women who remain symptomatic despite excellent conventional replacement. The risk-benefit calculation is quite different from most pharmaceutical interventions: the drug is inexpensive, the side effects are mild and reversible, and the deficiency being treated is real and measurable.